Update on the role of rituximab in kidney diseases and transplant

Bibliography

• Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006;2:221-30
   PubMedGoogle Scholar
• Einfeld DA, Brown JP, Valentine MA, Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7(3):711-17
   PubMed Web of Science ®Google Scholar
• Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989;264:11282-7
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33
   PubMed Web of Science ®Google Scholar
• Tedder TF, Boyd AW, Freedman AS, The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985;135:973-9
   PubMed Web of Science ®Google Scholar
• Press OW, Appelbaum F, Ledbetter JA, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008;87:345-64
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ, Madaio MP, Ni D, The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180:1295-306
   PubMed Web of Science ®Google Scholar
• Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005;238:67-75
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7
   PubMed Web of Science ®Google Scholar
• Kessel A, Rosner I, Toubi E. Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008;34:74-9
   PubMed Web of Science ®Google Scholar
• van den Hoogen MW, Hilbrands LB. Use of monoclonal antibodies in renal transplantation. Immunother 2011;3:871-80
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73
   PubMed Web of Science ®Google Scholar
• Tavazzi E, White MK, Khalili K. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol 2011; published online 20 September 2011; doi: 10.1002/rmv.710
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 2009;113:4834-40
   PubMed Web of Science ®Google Scholar
• Thaunat O, Morelon E, Defrance T. Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010;116:515-21
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767-76
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011;40:159-69
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8(3):R83
   PubMed Web of Science ®Google Scholar
• Lu TY, Ng KP, Cambridge G, A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010;70:529-40
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2458-66
   PubMed Web of Science ®Google Scholar
• Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010;11: published online 24 June 2010; doi:10.1186/1471-2369-11-12
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32
   PubMed Web of Science ®Google Scholar
• Guerry MJ, Brogan P, Bruce IN, Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2011; published online 25 May 2011; doi: 10.1093/rheumatology/ker150
   PubMedGoogle Scholar
• Monti G, Galli M, Invernizzi F, Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995;88:115-26
   PubMed Web of Science ®Google Scholar
• Garini G, Allegri L, Lannuzzella F, HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007;78:51-9
   PubMedGoogle Scholar
• Zaja F, De Vita S, Russo D, Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46:2252-4; author reply 2254–2255
   PubMed Web of Science ®Google Scholar
• Roccatello D, Baldovino S, Rossi D, Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008;34:111-17
   PubMed Web of Science ®Google Scholar
• Zaja F, Russo D, Fuga G, Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-8
   PubMed Web of Science ®Google Scholar
• Cacoub P, Delluc A, Saadoun D, Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-7
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G, Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116(3):326-34; quiz 504–505
   PubMed Web of Science ®Google Scholar
• Sugiura H, Takei T, Itabashi M, Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011;117:c98-c105
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Chiurchiu C, Brusegan V, Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003;;14:1851-7
   PubMed Web of Science ®Google Scholar
• Bomback AS, Derebail VK, McGregor JG, Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:734-44
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Abraham RS, Erickson SB, Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188-98
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Cosio FG, Erickson SB, Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-25
   PubMed Web of Science ®Google Scholar
• Cravedi P, Sghirlanzoni MC, Marasa M, Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 2011;33:461-8
   PubMed Web of Science ®Google Scholar
• Cravedi P, Ruggenenti P, Remuzzi G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol 2011;22:1400-2
   PubMed Web of Science ®Google Scholar
• Beck LH Jr, Fervenza FC, Beck DM, Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-50
   PubMed Web of Science ®Google Scholar
• van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881-92
   PubMed Web of Science ®Google Scholar
• Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978;13:159-65
   PubMed Web of Science ®Google Scholar
• Schulman SL, Kaiser BA, Polinsky MS, Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988;113:996-1001
   PubMed Web of Science ®Google Scholar
• Guigonis V, Dallocchio A, Baudouin V, Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008;23:1269-79
   PubMed Web of Science ®Google Scholar
• Kamei K, Ito S, Nozu K, Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009;24:1321-8
   PubMedGoogle Scholar
• Prytula A, Iijima K, Kamei K, Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010;25:461-8
   PubMed Web of Science ®Google Scholar
• Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007;356:2751-2
   PubMedGoogle Scholar
• Gulati A, Sinha A, Jordan SC, Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010;5:2207-12
   PubMed Web of Science ®Google Scholar
• Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 2010;14:314-25
   PubMed Web of Science ®Google Scholar
• Hickson LJ, Gera M, Amer H, Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009;87:1232-9
   PubMed Web of Science ®Google Scholar
• Evans RW, Manninen DL, Garrison LP, The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9
   PubMed Web of Science ®Google Scholar
• Port FK, Wolfe RA, Mauger EA, Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993;270:1339-43
   PubMed Web of Science ®Google Scholar
• Fuchinoue S, Ishii Y, Sawada T, The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011;91:853-7
   PubMed Web of Science ®Google Scholar
• Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R, Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-7
   PubMed Web of Science ®Google Scholar
• Paul LC, van Es LA, Riviere GB, Blood group B antigen on renal endothelium as the target for rejection in an ABO-incompatible recipient. Transplantation 1978;26:268-71
   PubMed Web of Science ®Google Scholar
• Imamura R, Ishiguro S, Shi Y, ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report. Xenotransplantation 2006;13:133-5
   PubMed Web of Science ®Google Scholar
• Sonnenday CJ, Warren DS, Cooper M, Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-22
   PubMed Web of Science ®Google Scholar
• Tyden G, Kumlien G, Genberg H, ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5:145-8
   PubMed Web of Science ®Google Scholar
• Toki D, Ishida H, Horita S, Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009;22:447-54
   PubMed Web of Science ®Google Scholar
• Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs.. risk. Am J Transplant 2003;3:1488-500
   PubMed Web of Science ®Google Scholar
• Cho YW, Cecka JM. Crossmatch tests–an analysis of UNOS data from 1991-2000. Clin Transpl 2001;237-46
   PubMedGoogle Scholar
• Vo AA, Lukovsky M, Toyoda M, Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-51
   PubMed Web of Science ®Google Scholar
• Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011;16:19-25
   PubMed Web of Science ®Google Scholar
• Lai CH, Cao K, Ong G, Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011;92:48-53
   PubMed Web of Science ®Google Scholar
• Tyden G, Genberg H, Tollemar J, A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009;87(9):1325-9
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Watson CJ, Plotnek G, B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009;360:2683-5
   PubMed Web of Science ®Google Scholar
• Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011;11:1359-67
   PubMed Web of Science ®Google Scholar
• Loupy A, Suberbielle-Boissel C, Zuber J, Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010;89:1403-10
   PubMed Web of Science ®Google Scholar
• Mulley WR, Hudson FJ, Tait BD, A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009;87:286-9
   PubMed Web of Science ®Google Scholar
• Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767-9
   PubMed Web of Science ®Google Scholar
• Oertel SH, Verschuuren E, Reinke P, Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-6
   PubMed Web of Science ®Google Scholar
• Jain AB, Marcos A, Pokharna R, Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005;80:1692-8
   PubMed Web of Science ®Google Scholar
• Evens AM, David KA, Helenowski I, Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038-46
   PubMed Web of Science ®Google Scholar